Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vudalimab - Xencor

Next Previous
X
Search
Drug Profile

Vudalimab - Xencor

Alternative Names: PD-1 x CTLA-4 - Xencor; XmAb 717; XmAb-20717

Latest Information Update: 04 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Gynaecological cancer; Prostate cancer; Urogenital cancer
  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 19 Sep 2024 Emory University in collaboration with Xencor suspends a phase I trial in Prostate cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (IV) to review the safety data (NCT05733351)
  • 27 Feb 2024 Efficacy and adverse events data from a phase II trial in Prostate cancer released by Xencor
  • 13 Feb 2024 M.D. Anderson Cancer Center in collaboration with Xencor withdrew phase II RX-CROME trial prior to enrolment in Colorectal cancer (IV) (NCT05900648)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top